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Background
The HIV/AIDS epidemic in Romania presents a series of
particularities linked to the high frequency of a particu-
lar HIV subtype, a subtype that hasn’t been found in
other European countries, clade F, and by the existence
of an important number of long life survivors patients
infected during 1988-1992 - today young adults who
presents a long history of treatment.
Purpose of the study
In order to evaluate the development of drug resistant
HIV strains, we sequenced the pol gene of HIV-1 iso-
lates from heavily treated patients.
Methods
The study included 26 HIV-1 isolates from heavily trea-
ted adolescents, with frequent changes in the antiretro-
viral combinations. Drug resistance genotyping was
performed using the TruGene HIV-1 Genotyping Assay
(Bayer Diagnostics). HIV subtype was determined using
the Stanford database algorithm.
Results
All the strains were found to belong to the F1 subtype.
65.4% of the patients presented resistance to at least one
of the 3 antiretroviral classes of used drugs (NRTI,
NNRTI and PIs ), while 15.4% were resistant to 2 classes
and only 7,7% were resistant to all 3 antiretroviral
classes. The most frequent substitutions of amino acids
in reverse transcriptase gene were from TAM2’s ("thy-
midine analogue mutations”): D67N, K70R, T215F,
K219Q/E-mutations that confer resistance to NRTI and
K103N, Y181C/I associated with primary resistance to
NNRTI. Only 23% from the patients presented substitu-
tions associated with major resistance to PI , the most
frequent: I47V, G48 G/V; I54V, V82A, that confer phe-
notypic resistance to regimens that include ritonavir as
a booster. As a surprise a series of minor and acces-
sories mutations were present in the protease gene
(ordered in decreased frequency: L10V, M36I; L63T,
K20M/R).
Conclusions
A follow up of the clinical progression rate of these
patients will provide important data, as subtype specific
resistance mutations have been reported and associated
with different rate of CD4 cell count decline over time
and with distinctive replicative fitness of the viral strain.
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